Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Export

@article{citeulike:3744138, abstract = {OBJECTIVE: The authors evaluated the effects of donepezil (10 mg/day) versus placebo on brain glucose metabolism. METHODS: This was a randomized, double-blind, parallel-group, 24-week pilot study in 28 patients with mild-to-moderate Alzheimer disease (AD). Functional brain activity was quantified by measuring average glucose metabolism in an axial brain slice and regional brain glucose metabolism using positron emission tomography. RESULTS: At Week 24, relative to the pons metabolic rate, mean brain glucose metabolism in an axial slice at the level of the striatum was maintained within 0.5\% of mean baseline levels for donepezil-treated patients, whereas it declined by an average of 10.4\% in placebo-treated patients. This observation was confirmed by an analysis of differences in the mean slopes of glucose metabolism in the striatal slice in donepezil- and placebo-treated patients during the 24-week period. Significant treatment differences at Week 24 favoring donepezil for the mean percentage change from baseline in regional brain glucose metabolism were observed in four predefined regions of interest: the right parietal lobe 1, left temporal lobe 2, right frontal lobe 2, and left frontal lobe 2. CONCLUSION: Placebo-treated patients with AD show a decline in functional brain activity, relative to the pons, in several regions, and treatment with donepezil may slow this decline.}, author = {Tune, L. and Tiseo, P. J. and Ieni, J. and Perdomo, C. and Pratt, R. D. and Votaw, J. R. and Jewart, R. D. and Hoffman, J. M.}, citeulike-article-id = {3744138}, citeulike-linkout-0 = {http://view.ncbi.nlm.nih.gov/pubmed/12611746}, citeulike-linkout-1 = {http://www.hubmed.org/display.cgi?uids=12611746}, issn = {1064-7481}, journal = {The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry}, keywords = {donepezil}, number = {2}, pages = {169--177}, posted-at = {2008-12-03 23:57:50}, priority = {2}, title = {Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study.}, url = {http://view.ncbi.nlm.nih.gov/pubmed/12611746}, volume = {11}, year = {2003} }

TY - JOUR ID - citeulike:3744138 L3 - citeulike-article-id:3744138 N2 - OBJECTIVE: The authors evaluated the effects of donepezil (10 mg/day) versus placebo on brain glucose metabolism. METHODS: This was a randomized, double-blind, parallel-group, 24-week pilot study in 28 patients with mild-to-moderate Alzheimer disease (AD). Functional brain activity was quantified by measuring average glucose metabolism in an axial brain slice and regional brain glucose metabolism using positron emission tomography. RESULTS: At Week 24, relative to the pons metabolic rate, mean brain glucose metabolism in an axial slice at the level of the striatum was maintained within 0.5% of mean baseline levels for donepezil-treated patients, whereas it declined by an average of 10.4% in placebo-treated patients. This observation was confirmed by an analysis of differences in the mean slopes of glucose metabolism in the striatal slice in donepezil- and placebo-treated patients during the 24-week period. Significant treatment differences at Week 24 favoring donepezil for the mean percentage change from baseline in regional brain glucose metabolism were observed in four predefined regions of interest: the right parietal lobe 1, left temporal lobe 2, right frontal lobe 2, and left frontal lobe 2. CONCLUSION: Placebo-treated patients with AD show a decline in functional brain activity, relative to the pons, in several regions, and treatment with donepezil may slow this decline. IS - 2 JF - The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry SN - 1064-7481 EP - 177 TI - Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. VL - 11 SP - 169 KW - donepezil AU - Tune, L AU - Tiseo, PJ AU - Ieni, J AU - Perdomo, C AU - Pratt, RD AU - Votaw, JR AU - Jewart, RD AU - Hoffman, JM PY - 2003///r UR - http://view.ncbi.nlm.nih.gov/pubmed/12611746 ER -